However, with the advent ofHER2-targeted therapy, the natural history of HER2-positive breast cancer has been dramatically improved (Ferretti,Fabi, Felici, & Papaldo, 2010; Dawood, Broglio, Buzdar, Hortobagyi, & Giordano, 2010). Here, ERBB2 is linked to breast carcinoma.